Do analysts recommend HIK or INDV?

Hikma Pharmaceuticals presently has a consensus target price of GBX 1,687, suggesting a potential upside of 7.80%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Hikma Pharmaceuticals is more favorable than Indivior. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hikma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Indivior 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer HIK or HCM?

Hikma Pharmaceuticals currently has a consensus price target of GBX 1,687, suggesting a potential upside of 7.80%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Hikma Pharmaceuticals is more favorable than HUTCHMED. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hikma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 HUTCHMED 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate HIK or AMYT?

Hikma Pharmaceuticals currently has a consensus target price of GBX 1,687, indicating a potential upside of 7.80%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Hikma Pharmaceuticals is more favorable than Amryt Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hikma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Amryt Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend HIK or AGY?

Hikma Pharmaceuticals currently has a consensus price target of GBX 1,687, indicating a potential upside of 7.80%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Hikma Pharmaceuticals is more favorable than Allergy Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hikma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Allergy Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend HIK or APH?

Hikma Pharmaceuticals currently has a consensus target price of GBX 1,687, suggesting a potential upside of 7.80%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Hikma Pharmaceuticals is more favorable than Alliance Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hikma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Alliance Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Hikma Pharmaceuticals (HIK) Competitors

GBX 1,565 +14.00 (+0.90%)

As of 08:33 AM Eastern

Compare

HIK vs. INDV, HCM, AMYT, AGY, and APH

Should you buy Hikma Pharmaceuticals stock or one of its competitors? MarketBeat compares Hikma Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hikma Pharmaceuticals include Indivior (INDV), HUTCHMED (HCM), Amryt Pharma (AMYT), Allergy Therapeutics (AGY), and Alliance Pharma (APH). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Hikma Pharmaceuticals compare to Indivior?

Hikma Pharmaceuticals (LON:HIK) and Indivior (LON:INDV) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

Hikma Pharmaceuticals has a beta of 0.654, meaning that its share price is 35% less volatile than the broader market. Comparatively, Indivior has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

63.6% of Hikma Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.0% of Indivior shares are owned by institutional investors. 21.9% of Hikma Pharmaceuticals shares are owned by company insiders. Comparatively, 3.4% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Hikma Pharmaceuticals has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	£3.35B	0.98	£353.21M	£181.00	8.65
Indivior	£1.40B	1.38	-£2.36M	-£1.21	N/A

Hikma Pharmaceuticals has a net margin of 12.00% compared to Indivior's net margin of 11.44%. Hikma Pharmaceuticals' return on equity of 15.83% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	12.00%	15.83%	9.40%
Indivior	11.44%	-23.90%	2.37%

Hikma Pharmaceuticals pays an annual dividend of GBX 84.14 per share and has a dividend yield of 5.4%. Indivior pays an annual dividend of GBX 15 per share and has a dividend yield of 1.2%. Hikma Pharmaceuticals pays out 46.5% of its earnings in the form of a dividend. Indivior pays out -1,243.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Hikma Pharmaceuticals presently has a consensus target price of GBX 1,687, suggesting a potential upside of 7.80%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Hikma Pharmaceuticals is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Indivior	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Hikma Pharmaceuticals had 2 more articles in the media than Indivior. MarketBeat recorded 2 mentions for Hikma Pharmaceuticals and 0 mentions for Indivior. Hikma Pharmaceuticals' average media sentiment score of 0.75 beat Indivior's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Hikma Pharmaceuticals	Positive
Indivior	Neutral

Summary

Hikma Pharmaceuticals beats Indivior on 15 of the 18 factors compared between the two stocks.

How does Hikma Pharmaceuticals compare to HUTCHMED?

Hikma Pharmaceuticals (LON:HIK) and HUTCHMED (LON:HCM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

Hikma Pharmaceuticals has a beta of 0.654, meaning that its share price is 35% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.428, meaning that its share price is 57% less volatile than the broader market.

Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	£3.35B	0.98	£353.21M	£181.00	8.65
HUTCHMED	£548.51M	2.74	-£52.98M	£53.00	3.30

In the previous week, Hikma Pharmaceuticals had 2 more articles in the media than HUTCHMED. MarketBeat recorded 2 mentions for Hikma Pharmaceuticals and 0 mentions for HUTCHMED. Hikma Pharmaceuticals' average media sentiment score of 0.75 beat HUTCHMED's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Hikma Pharmaceuticals	Positive
HUTCHMED	Neutral

Hikma Pharmaceuticals currently has a consensus price target of GBX 1,687, suggesting a potential upside of 7.80%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
HUTCHMED	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

63.6% of Hikma Pharmaceuticals shares are held by institutional investors. Comparatively, 20.4% of HUTCHMED shares are held by institutional investors. 21.9% of Hikma Pharmaceuticals shares are held by company insiders. Comparatively, 2.8% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

HUTCHMED has a net margin of 163.84% compared to Hikma Pharmaceuticals' net margin of 12.00%. HUTCHMED's return on equity of 36.88% beat Hikma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	12.00%	15.83%	9.40%
HUTCHMED	163.84%	36.88%	-5.90%

Summary

Hikma Pharmaceuticals beats HUTCHMED on 13 of the 16 factors compared between the two stocks.

How does Hikma Pharmaceuticals compare to Amryt Pharma?

Hikma Pharmaceuticals (LON:HIK) and Amryt Pharma (LON:AMYT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Hikma Pharmaceuticals has a net margin of 12.00% compared to Amryt Pharma's net margin of 0.00%. Hikma Pharmaceuticals' return on equity of 15.83% beat Amryt Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	12.00%	15.83%	9.40%
Amryt Pharma	N/A	N/A	N/A

In the previous week, Hikma Pharmaceuticals had 2 more articles in the media than Amryt Pharma. MarketBeat recorded 2 mentions for Hikma Pharmaceuticals and 0 mentions for Amryt Pharma. Hikma Pharmaceuticals' average media sentiment score of 0.75 beat Amryt Pharma's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Hikma Pharmaceuticals	Positive
Amryt Pharma	Neutral

Hikma Pharmaceuticals has higher revenue and earnings than Amryt Pharma. Amryt Pharma is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	£3.35B	0.98	£353.21M	£181.00	8.65
Amryt Pharma	£210.24M	0.00	N/A	-£33.00	N/A

63.6% of Hikma Pharmaceuticals shares are held by institutional investors. 21.9% of Hikma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Hikma Pharmaceuticals currently has a consensus target price of GBX 1,687, indicating a potential upside of 7.80%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Hikma Pharmaceuticals is more favorable than Amryt Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Amryt Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Hikma Pharmaceuticals beats Amryt Pharma on 13 of the 13 factors compared between the two stocks.

How does Hikma Pharmaceuticals compare to Allergy Therapeutics?

Hikma Pharmaceuticals (LON:HIK) and Allergy Therapeutics (LON:AGY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Hikma Pharmaceuticals has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	£3.35B	0.98	£353.21M	£181.00	8.65
Allergy Therapeutics	£57.29M	7.63	-£52.59M	-£0.97	N/A

Hikma Pharmaceuticals currently has a consensus price target of GBX 1,687, indicating a potential upside of 7.80%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Hikma Pharmaceuticals is more favorable than Allergy Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Allergy Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Hikma Pharmaceuticals had 2 more articles in the media than Allergy Therapeutics. MarketBeat recorded 2 mentions for Hikma Pharmaceuticals and 0 mentions for Allergy Therapeutics. Hikma Pharmaceuticals' average media sentiment score of 0.75 beat Allergy Therapeutics' score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Hikma Pharmaceuticals	Positive
Allergy Therapeutics	Neutral

Hikma Pharmaceuticals has a net margin of 12.00% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Hikma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	12.00%	15.83%	9.40%
Allergy Therapeutics	-85.46%	409.00%	-34.76%

63.6% of Hikma Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Allergy Therapeutics shares are owned by institutional investors. 21.9% of Hikma Pharmaceuticals shares are owned by insiders. Comparatively, 3.6% of Allergy Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Hikma Pharmaceuticals has a beta of 0.654, indicating that its share price is 35% less volatile than the broader market. Comparatively, Allergy Therapeutics has a beta of 0.872, indicating that its share price is 13% less volatile than the broader market.

Summary

Hikma Pharmaceuticals beats Allergy Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Hikma Pharmaceuticals compare to Alliance Pharma?

Hikma Pharmaceuticals (LON:HIK) and Alliance Pharma (LON:APH) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

Hikma Pharmaceuticals pays an annual dividend of GBX 84.14 per share and has a dividend yield of 5.4%. Alliance Pharma pays an annual dividend of GBX 2 per share and has a dividend yield of 3.1%. Hikma Pharmaceuticals pays out 46.5% of its earnings in the form of a dividend. Alliance Pharma pays out -32.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Hikma Pharmaceuticals has a net margin of 12.00% compared to Alliance Pharma's net margin of -6.00%. Hikma Pharmaceuticals' return on equity of 15.83% beat Alliance Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	12.00%	15.83%	9.40%
Alliance Pharma	-6.00%	-5.04%	5.98%

Hikma Pharmaceuticals currently has a consensus target price of GBX 1,687, suggesting a potential upside of 7.80%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Hikma Pharmaceuticals is more favorable than Alliance Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Alliance Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

63.6% of Hikma Pharmaceuticals shares are owned by institutional investors. Comparatively, 66.3% of Alliance Pharma shares are owned by institutional investors. 21.9% of Hikma Pharmaceuticals shares are owned by company insiders. Comparatively, 12.0% of Alliance Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Hikma Pharmaceuticals has higher revenue and earnings than Alliance Pharma. Alliance Pharma is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	£3.35B	0.98	£353.21M	£181.00	8.65
Alliance Pharma	£183.50M	1.91	-£33.65M	-£6.20	N/A

Hikma Pharmaceuticals has a beta of 0.654, indicating that its stock price is 35% less volatile than the broader market. Comparatively, Alliance Pharma has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

In the previous week, Hikma Pharmaceuticals had 2 more articles in the media than Alliance Pharma. MarketBeat recorded 2 mentions for Hikma Pharmaceuticals and 0 mentions for Alliance Pharma. Hikma Pharmaceuticals' average media sentiment score of 0.75 beat Alliance Pharma's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Hikma Pharmaceuticals	Positive
Alliance Pharma	Neutral

Summary

Hikma Pharmaceuticals beats Alliance Pharma on 14 of the 18 factors compared between the two stocks.

Get Hikma Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HIK vs. The Competition

Export

Metric	Hikma Pharmaceuticals	Drug Manufacturers Industry	Medical Sector	LON Exchange
Market Cap	£3.29B	£5.83B	£6.96B	£2.78B
Dividend Yield	4.12%	2.82%	2.68%	6.12%
P/E Ratio	8.65	5.05	27.19	368.14
Price / Sales	0.98	1,648.44	576.75	84,690.07
Price / Cash	8.34	10.18	49.25	27.89
Price / Book	1.52	10.29	10.73	7.49
Net Income	£353.21M	£20.27B	£3.59B	£5.89B
7 Day Performance	-2.07%	-0.27%	-1.97%	0.02%
1 Month Performance	7.05%	-0.41%	2.18%	-1.37%
1 Year Performance	-21.55%	7.75%	23.78%	62.12%

Hikma Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HIK Hikma Pharmaceuticals	3.1638 of 5 stars	GBX 1,565 +0.9%	GBX 1,687 +7.8%	-24.0%	£3.29B	£3.35B	8.65	9,100	Analyst Forecast
INDV Indivior	N/A	GBX 1,238 +1.6%	N/A	+8.5%	£1.93B	£1.40B	N/A	1,000	Gap Up High Trading Volume
HCM HUTCHMED	N/A	GBX 172 flat	N/A	-30.0%	£1.48B	£548.51M	3.25	1,760	Gap Up
AMYT Amryt Pharma	N/A	N/A	N/A	N/A	£457.11M	£210.24M	N/A	290	Gap Down
AGY Allergy Therapeutics	N/A	GBX 6.39 -3.3%	N/A	-21.2%	£404.33M	£57.29M	N/A	612

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:HIK) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hikma Pharmaceuticals (HIK) Competitors

HIK vs. INDV, HCM, AMYT, AGY, and APH

How does Hikma Pharmaceuticals compare to Indivior?

Summary

How does Hikma Pharmaceuticals compare to HUTCHMED?

Summary

How does Hikma Pharmaceuticals compare to Amryt Pharma?

Summary

How does Hikma Pharmaceuticals compare to Allergy Therapeutics?

Summary

How does Hikma Pharmaceuticals compare to Alliance Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HIK vs. The Competition

Hikma Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hikma Pharmaceuticals (HIK) Competitors

HIK vs. INDV, HCM, AMYT, AGY, and APH

How does Hikma Pharmaceuticals compare to Indivior?

Which has more volatility & risk, HIK or INDV?

Do insiders and institutionals have more ownership in HIK or INDV?

Which has preferable valuation and earnings, HIK or INDV?

Is HIK or INDV more profitable?

Is HIK or INDV a better dividend stock?

Do analysts recommend HIK or INDV?

Does the media refer more to HIK or INDV?

Summary

How does Hikma Pharmaceuticals compare to HUTCHMED?

Which has more risk & volatility, HIK or HCM?

Which has preferable valuation and earnings, HIK or HCM?

Does the media favor HIK or HCM?

Do analysts prefer HIK or HCM?

Do insiders and institutionals believe in HIK or HCM?

Is HIK or HCM more profitable?

Summary

How does Hikma Pharmaceuticals compare to Amryt Pharma?

Is HIK or AMYT more profitable?

Does the media refer more to HIK or AMYT?

Which has preferable valuation & earnings, HIK or AMYT?

Do insiders and institutionals have more ownership in HIK or AMYT?

Do analysts rate HIK or AMYT?

Summary

How does Hikma Pharmaceuticals compare to Allergy Therapeutics?

Which has stronger earnings & valuation, HIK or AGY?

Do analysts recommend HIK or AGY?

Does the media prefer HIK or AGY?

Is HIK or AGY more profitable?

Do institutionals & insiders believe in HIK or AGY?

Which has more volatility and risk, HIK or AGY?

Summary

How does Hikma Pharmaceuticals compare to Alliance Pharma?

Is HIK or APH a better dividend stock?

Is HIK or APH more profitable?

Do analysts recommend HIK or APH?

Do institutionals and insiders hold more shares of HIK or APH?

Which has stronger valuation & earnings, HIK or APH?

Which has more volatility and risk, HIK or APH?

Does the media refer more to HIK or APH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HIK vs. The Competition

Hikma Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools